Catalyst/ligand-free synthesis of benzimidazoles and quinazolinones from amidines via intramolecular transamination reaction
摘要:
An efficient catalyst/ligand-free synthesis of benzimidazoles and quinazolinones from amidines in quailtitative yields has been described. (C) 2010 Elsevier Ltd. All rights reserved.
Rhodium-Catalyzed C–H Activation of 2-Arylquinazolinones and Cyclization with Elemental Sulfur via C–S/S–N Bond Formation to Access 7H-Benzo[4,5]isothiazolo[3,2-b]quinazolinones
作者:Yiyuan Peng、Xinqin Zhang、Qiong Wu、Qin Yang、Yang Fu
DOI:10.1055/a-2147-2620
日期:2023.10
An efficient method for the synthesis of 7H-benzo[4,5]isothiazolo[3,2-b]quinazolin-7-ones by the reaction of 2-arylquinazolin-4(3H)-ones and elemental sulfur is described. The rhodium-catalyzed C–H activation of 2-arylquinazolinones and cyclization with elemental sulfur via one-step formation of C–S/N–S bonds to give the corresponding 7H-benzo[4,5]isothiazolo[3,2-b]quinazolinones is realized in good
描述了一种通过2-芳基喹唑啉-4(3 H )-酮与元素硫反应合成7 H-苯并[4,5]异噻唑并[3,2- b ]喹唑啉-7-酮的有效方法。铑催化 2-芳基喹唑啉酮的 C-H 活化,并通过一步形成 C-S/N-S 键与元素硫环化,得到相应的 7 H-苯并[4,5]异噻唑啉酮[ 3,2- b ]喹唑啉酮类化合物的产率从良好到高,且具有良好的官能团耐受性。
[EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2012151195A1
公开(公告)日:2012-11-08
Hepatitis C virus inhibitors having the following general formula (I); are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Catalyst/ligand-free synthesis of benzimidazoles and quinazolinones from amidines via intramolecular transamination reaction
作者:Sahaj Gupta、Piyush K. Agarwal、Bijoy Kundu
DOI:10.1016/j.tetlet.2010.02.019
日期:2010.4
An efficient catalyst/ligand-free synthesis of benzimidazoles and quinazolinones from amidines in quailtitative yields has been described. (C) 2010 Elsevier Ltd. All rights reserved.
Discovery of Small Molecules Targeting the Frameshifting Element RNA in SARS-CoV-2 Viral Genome
作者:Mo Yang、Feyisola P. Olatunji、Curran Rhodes、Sumirtha Balaratnam、Kara Dunne-Dombrink、Srinath Seshadri、Xiao Liang、Christopher P. Jones、Stuart F. J. Le Grice、Adrian R. Ferré-D’Amaré、John S. Schneekloth
DOI:10.1021/acsmedchemlett.3c00051
日期:2023.6.8
orthogonal biophysical assays and structure–activity relationship (SAR) studies. This work reveals compounds with mid-micromolar binding affinity (KD = 60 ± 6 μM) to the FSE RNA and supports a binding mode distinct from previously reported FSE binders MTDB and merafloxacin. In addition, compounds are active in in vitro dual-luciferase and in-cell dual-fluorescent-reporter frameshifting assays, highlighting